| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
Akers Biosciences is a Thorofare, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
World Wide Webmasters is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.
Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.